×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
GeneticVariation
BEFREE
<b>Objective:</b> The COMBI-AD trial demonstrated the efficacy and safety of dabrafenib and trametinib in combination vs placebo as adjuvant treatment of patients with BRAF V600E /K mutation-positive resected Stage IIIA (lymph node metastasis >1 mm), IIIB, or IIIC melanoma.
31223037 2019
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
GeneticVariation
BEFREE
Lymph node metastases of melanoma: challenges for BRAF mutation detection.25456393 2015
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
GeneticVariation
BEFREE
Lymph node metastasis and BRAF V600E mutations were more frequent in papillary thyroid cancers with high LOC100507661 expression.27151833 2016
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
GeneticVariation
BEFREE
BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases .17685465 2007
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
GeneticVariation
BEFREE
BRAF mutations appear to play a role in the tumorigenesis of a subset of ATCs, and the majority of lymph node metastases .17989125 2008
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
GeneticVariation
BEFREE
BRAF mutation-positive PTMCs were more likely to manifest aggressive characteristics (extrathyroidal extension and LNM ).20953721 2010
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
GeneticVariation
BEFREE
BRAF mutation examined in FNAB specimens, compared with the wild-type allele, strongly predicted perithyroidal invasion (48 vs. 29%; P = 0.017), extracapsular spread (65 vs. 45%; P = 0.017), occult central lymph node metastasis (35 vs. 15%; P = 0.004), and advanced TNM stage (44 vs. 28%; P = 0.035).22930785 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
GeneticVariation
BEFREE
BRAF mutation was associated with lymph node metastases (LNM ), advanced stage, extrathyroidal extension, tumor size, male gender, multifocality, absence of capsule, classic PTC, and tall-cell variant PTC.23055546 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
GeneticVariation
BEFREE
BRAF mutation was not found to be significantly associated with the presence of LNM (P = .167).23062653 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
Biomarker
BEFREE
BRAF was not correlated with lymph node metastases .23186006 2013
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
Biomarker
BEFREE
BRAF positive tumours had a significantly higher rate of subsequent lymph node metastases (p=0.035).24247620 2013
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
GeneticVariation
BEFREE
BRAF (V600E ) mutation-positive cancers (55.3%) were more frequently associated with lymph node metastasis (p=0.01) and advanced TNM stage (III-IV) (p=0.03).24787545 2014
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
GeneticVariation
BEFREE
BRAF V600E mutation status was not associated with clinicopathologic characteristics of aggressive behavior such as extrathyroidal extension, lymph node metastases , higher T-categories, male sex, and greater age.25482468 2015
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
GeneticVariation
BEFREE
BRAF gene mutations independently predicted central lymph node metastasis in patients with papillary thyroid carcinoma.26214416 2015
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
GeneticVariation
BEFREE
BRAF mutation was not associated with central lymph node metastasis in other tumor sizes.26268700 2016
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
GeneticVariation
BEFREE
BRAF (V600E ) in PTC predicts an increased risk of lymph node metastasis , extra-thyroidal extension and reduced disease-free survival.27138882 2016
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
Biomarker
BEFREE
BRAF -positive malignancies were more likely to demonstrate extrathyroidal extension (P = .003), lymphovascular invasion (P = .02), and lymph node metastasis (P < .001).27689252 2016
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
Biomarker
BEFREE
BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases .28680105 2017
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
GeneticVariation
BEFREE
BRAF mutation was associated with lymph node metastasis (adjusted RRR 2.46 95% CI 1.07-5.69, P=0.04) and sentinel lymph node positivity (adjusted odds ratio [aOR] OR 1.55, 95% CI 1.14-2.10, P=0.005).28787433 2017
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
GeneticVariation
BEFREE
BRAF V600E was associated with aggressive tumor factors, including lymph node metastasis (P=0.001) and advanced disease stage (P=0.009).31602213 2019
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
GeneticVariation
BEFREE
Additional genotyping of PTC cases for the BRAFV600E mutation revealed for the first time a close relation between SLP-2 overexpression and the presence of BRAF mutation (p = 0.02) with high positive rates of lymph node metastasis (70%) and extrathyroid invasion (80%) in these cases.
26750533 2016
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
GeneticVariation
BEFREE
Additionally, there were significant associations (P<0.05) between BRAF (V600E ) and a higher tumor-node-metastasis staging (III/IV), and between miR-21* over-expression and lymph node metastasis .
23416953 2013
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
AlteredExpression
BEFREE
Among patients with wild-type BRAF , the expression of these 2 lncRNAs showed significantly higher levels in the patients with lymph node metastasis .
27459529 2016
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
GeneticVariation
BEFREE
Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
26950846 2016
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of lymph node
0.100
GeneticVariation
BEFREE
By contrast, positive status of BRAF (V600E ) mutation was a significant predictor of multifocality (OR = 1.23; 95%CI = 1.14-1.32), extrathyroidal extension (OR = 2.23; 95%CI = 1.90-2.63), TNM stage (OR = 1.67; 95%CI = 1.53-1.81), lymph node metastasis (OR = 1.67; 95%CI = 1.45-1.93), vascular invasion (OR = 1.47; 95%CI = 1.22-1.79) and recurrence/persistence (OR = 2.33; 95%CI = 1.71-3.18).
26871894 2016